Aimmune Therapeutics

Aimmune Therapeutics is a company operating in the United States biotechnology industry. Its main focus is in the development of product candidates to combat peanut and other food allergies. The company's therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy, is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols, and support services.

Aimmune's (AIMT) peanut allergy drug gets majority of votes from the Advisory Committee of the FDA.

Aimmune's Peanut Allergy Drug Gets FDA Committee's Support

A Food and Drug Administration panel determined Friday the benefits of Aimmune Therapeutics' peanut allergy treatment outweigh the risks. The panel voted 8-1 in favor of the drug's safety.

A Mixed FDA Panel Just Recommended This Biotech's Peanut Allergy Drug

Aimmune Therapeutics Inc.'s stock aimm has been halted for news Friday, as the Food and Drug Administration's Allergenic Products Advisory Committee (APAC) is meeting about the efficacy and safety data of the biopharmaceutical company's treatment for peanut allergies, Palforzia.

Aimmune's stock halted as FDA panel's decision awaited on peanut allergy treatment

Here's what a benign briefing document means, and what it doesn't.

Did the FDA Just Signal Smooth Sailing Ahead For Aimmune Therapeutics?

Most people are aware that peanuts can cause a severe, potentially life-threatening allergic reactions, which can be unpredictable, and even minuscule amounts of peanut can cause a disaster.

Potential Peanut Allergy Treatment Gives Pharma Company A Boost

The company's peanut allergen desensitization therapy took an indirect step forward.

Here's Why Aimmune Therapeutics Stock Is Surging Today

Aimmune Therapeutics stock rocketed to a six-month high Wednesday ahead of a Food and Drug Administration committee meeting to discuss the biotech company's peanut allergy treatment.

Why This Peanut Allergy-Focused Biotech Stock Rocketed In Huge Volume

Aimmune Therapeutics Inc (NASDAQ: AIMT) shares have been on an extended downtrend since the start of 2018.

Biotech Stock On The Radar: Aimmune Awaits Adcom Test

Alnylam Pharmaceuticals

Moderna

Investors better get ready for a busy week ahead.

3 Biotech Stocks That Could Soar This Week

Investors need to pay close attention to Aimmune (AIMT) stock based on the movements in the options market lately.

Implied Volatility Surging for Aimmune (AIMT) Stock Options

AIMT has produced excellent results in pivotal trials for AR101 in peanut allergy.

Aimmune Therapeutics: A Catalyst-Driven Buy Before Advisory Committee Meeting

Aimmune published highly robust Phase 3 (RAMSES, ARTEMIS, and PALISADE) data for AR101. Therefore, the drug is positioned to gain FDA approval for treating peanut allergy by January 2020.

Aimmune: Contextualizing The ICER Statement

Aimmune Therapeutics, Inc. (AIMT) CEO Jayson Dallas on Q2 2019 Results - Earnings Call Transcript

Aimmune's (AIMT) peanut allergy candidate AR101 attracts negative review from ICER, stating risks outweighs benefits in patients. AR101 is under review and a decision is expected by January 2020.

Aimmune Down on Negative ICER Review on Allergy Candidate

The Institute for Clinical and Economic Review questions the short-term risks of the biotech's drug.

Here's Why Aimmune Therapeutics Fell 7% Today

Aimmune Therapeutics (AIMT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes Aimmune Therapeutics (AIMT) a New Buy Stock

AbbVie

Alexion Pharma

bluebird bio

These drugs and the biotechs that make them could be on the way to tremendous success in the near future.

Top 5 New Drug Launches of 2019 -- and the Biotech Stocks That Could Win Big

Aimmune Therapeutics is a leading innovator to deliver the "silver bullet" for food allergies.

Aimmune: Delivering The Silver Bullets For Various Food Allergies

Aimmune Therapeutics, Inc. (AIMT) CEO Jayson Dallas on Q1 2019 Results - Earnings Call Transcript

These four experimental drugs will reach the market soon, and the companies launching them have little room for error.

News for Aimmune Therapeutics Stock (AIMT)